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The use of a female donor for a male recipient is known to
have a greater early mortality (OR=1.11, P=0.3), similarly to
that of a recipient using vasoactive drugs and waiting in the inten-
sive care unit (OR=2.51, P<0.0001)13-15.
We report the case of a patient undergoing orthotopic cardiac
transplantation, who experienced cardiogenic shock due to right
ventricular dysfunction secondary to pulmonary hypertension as-
sociated with vasoplegia. Because the recipient’s clinical condition
was critical, a marginal donor was used.
In the national literature, we did not find reports of the use of
sildenafil for pulmonary hypertension in the postoperative period.
The objective of this report is to propose a new and safe manner
to treat right ventricular failure secondary to pulmonary hyperten-
sion in the postoperative period of cardiac transplantation.
Case Report
The patient was a 33-year-old man with idiopathic dilated cardio-
myopathy, who had been in NYHA functional class IV for the prece-
ding 2 years and was hospitalized with low cardiac output and was
using catecholamines (dobutamine, 6.6 mcg/kg/min, and dopamine,
8 mcg/kg/min). The patient was hypotensive (blood pressure of
70x40 mmHg), slightly dyspneic at rest, and had hepatomegaly
and pulmonary congestion (basal rales in both bases).
The patient underwent orthotopic cardiac transplantation on
08/02/2003. Due to his rapid clinical worsening, a marginal organ
was used. The marginal donor was a 60-kg female, who had
experienced cardiac arrest for 15 minutes 3 days before, was
using 12 mcg/kg/min of dopamine, and, on the echocardiogram,
had diffuse, mild hypokinesia and preserved overall function.
The transplantation was performed according to the bicaval
technique with 165 minutes of extracorporeal circulation and 117
minutes of anoxia, under mild hypothermia (32oC) and use of inter-
mittent anterograde blood cardioplegia. The patient was removed
from the extracorporeal circulation after the third attempt and sent
to the ICU receiving 0.11 mcg/kg/min of isoproterenol, 0.75 mcg/
kg/min milrinone, and 20mcg/kg/min of dobutamine. His mean blood
pressure was 40 mmHg and mean pulmonary arterial pressure was
45 mmHg. His right ventricular contractility was very poor, and he
received adrenaline in bolus during transportation and in the first
hours at the ICU. Twelve hours after transplantation, the patient
was receiving 10mcg/kg/min of dobutamine, 0.96 mcg/kg/min of
adrenaline, 0.13 mcg/kg/min of isoproterenol, and 0.41 mcg/kg/
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We report the case of a male patient who underwent ortho-
topic cardiac transplantation. A marginal donor was used, be-
cause the recipient’s clinical condition was critical. He expe-
rienced cardiogenic shock due to right ventricular dysfunction
secondary to pulmonary hypertension associated with vasoplegia.
After the introduction of sildenafil, the patient recovered hemo-
dynamically, his pulmonary vascular resistance decreased, the
vasoactive drugs were withdrawn, and his right ventricular func-
tion improved.
The use of inhaled nitric oxide reduces pulmonary artery pres-
sure, increasing the production of guanosine 3’,5’-cyclic mono-
phosphate (GMPc) in the smooth muscle cells of the lung 1.
Specific inhibitors of GMPc phosphodiesterase (PDE5), which
hydrolyzes GMPc in vascular smooth muscle, cause pulmonary
vasodilation 2-4.
Sildenafil is a specific inhibitor of PDE5 that increases the
pulmonary vasodilating effect of inhaled nitric oxide 5-8, prevents
pulmonary hypertensive crises after weaning of nitric oxide in pa-
tients with severe pulmonary hypertension 5,9, and has its own
pulmonary vasodilating effect 10,11 by increasing the GMPc levels 12.
Molina et al 11 reported a 20% reduction in the PAP of a
patient with pulmonary hypertension due to systemic lupus ery-
thematosus, who had suprasystemic pulmonary pressure levels,
with elevated doses of sildenafil (1600 mg per day). The authors
reported a good tolerance to the medication.
In an experimental study, Weimann et al 10 showed that the
pulmonary vasodilating effect of sildenafil is dose-dependent, be-
ginning 5 minutes after its administration and reaching its maxi-
mum effect in 10 minutes.
Michelakis et al 12 showed that patients with pulmonary hy-
pertension who are candidates for cardiac transplantation had a
decrease in pulmonary vascular resistance that was more prominent
with sildenafil alone, at the dosage of 75mg, than with inhaled
nitric oxide in 80 ppm, associated with a significant increase in
GMPc levels.
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min of noradrenaline, and his mean blood pressure was 63 mmHg.
His clinical condition was clearly worsening, with pulmonary hy-
pertension associated with vasoplegia. The use of vasoconstrictors
for vasoplegia (systemic vascular resistance = 238 D.s/cm5) was
hindered by pulmonary hypertension.
As the patient evolved with aggravation of the hemodynamic
condition and oliguria, 150 mg of sildenafil was administered
through a nasogastric probe (4:30 PM on 08/03/03). The pulmo-
nary vascular resistance significantly decreased (tab. I), allowing
the use of greater doses of vasoconstrictors (noradrenaline) for
treating vasoplegia, and the following values were obtained: pul-
monary vascular resistance of 86 D.s/cm5 (1.08 Wood) and syste-
mic vascular resistance of 762 D.s/cm5. Sildenafil was maintained
at the dosage of 50mg every 8 hours, allowing, on the following
day, a significant drop in pulmonary arterial pressure and in CVP,
without pulmonary hypertension even with the use of noradrenaline.
The echocardiograms in the immediate postoperative period
and third postoperative day showed a significant right ventricular
deficit. However, the hemodynamic measurements showed an
improvement in right ventricular performance and a sustained drop
in pulmonary vascular resistance. The suspension of the vasoactive
drugs was progressive, and the echocardiogram on the sixth pos-
toperative day showed a mild right ventricular deficit. The patient
was discharged from the ICU on the eighth postoperative day,
and the use of sildenafil was maintained until the 15th postoperative
day. The echocardiogram of the 17th postoperative day showed
a preserved biventricular function, mild tricuspid regurgitation,
and pulmonary arterial pressure of 45 mmHg. The immunosup-
pressive scheme used comprised prednisone, mycophenolate mo-
fetil, and cyclosporine. So far, the endomyocardial biopsies have
shown no sign of rejection.
Discussion
The patient studied had preoperative pulmonary hypertension
(PAP=52 mmHg) even while using dobutamine. Despite the short
period of ischemia (117 minutes), severe right ventricular dys-
function developed, being attributed to pulmonary hypertension.
The overlapping vasoplegia, secondary to either extracorporeal
circulation or the use of vasodilators (dobutamine, isoproterenol,
milrinone), made the patient’s management difficult, because the
increase in the doses of vasoconstrictors aggravated pulmonary
hypertension.
The use of sildenafil caused significant pulmonary vasodilation
without causing systemic vasodilation. Its specific pulmonary va-
sodilating effect allowed the use of high doses of vasoconstrictors
(noradrenaline and adrenaline) for the treatment of vasoplegia
without causing pulmonary vasoconstriction. The catecholamines
were suspended and the right ventricular function recovered, which
was evident on serial echocardiography.
Patient candidates for cardiac transplantation, in whom a pul-
monary vascular resistance lower than 2.5 Wood units is not ob-
tained with a vasodilator without systemic hypotension or with
elevated pulmonary arterial pressure (PAP >50 mmHg), have a
significant increase in early mortality due to graft failure after
transplantation 14,15. Graft failure accounts for 38.7% of the deaths
in the first 30 days after transplantation 13.
Mychaskiw et al 9 reported a surprising hemodynamic impro-
vement in a patient with a device for left and right ventricular
support waiting for cardiac transplantation, who was experiencing
clear hemodynamic worsening due to a pulmonary hypertension
crisis, 20 minutes after receiving 50 mg of sildenafil. The authors
managed to interrupt the treatment with nitric oxide and cate-
cholamines, and extubate the patient who seemed to have an
irreversible clinical worsening.
Sildenafil is rapidly absorbed through the gastrointestinal tract,
even in critically ill patients 6. High doses (400 mg, 4 times a
day) of sildenafil are well tolerated and have few significant side
effects (hypotension, significant cephalea) 11.
Therefore, we believe that sildenafil may be adequate for the
postoperative period of patients undergoing cardiac transplantation,
who have significant right ventricular dysfunction, and even in
patients in critical condition, as long as the drug is adequately
absorbed, even in poor clinical conditions.
Table I - Hemodynamic measures for thermodilution with the Swan-Ganz catheter and catecholamines used in the postoperative period
Sildenafil
08/03/03 08/03/03 08/03/03 08/04/03 08/04/03
11:20 16:35 20:30 01:15 15:00
MBP (mmHg) 65 62 92 93 66
PAP (mmHg) 38 35 33 31 27
CVP (mmHg) 36 34 30 26 23
PCP (mmHg) 22 21 26 21 21
SVR (D.s/cm5) 368 238 762 939 603
PVR (D.s/cm5) 203 155 86 140 84
Dobutamine (mcg/kg/min) 9.6 16.0 16 16 16
Adrenaline (mcg/kg/min) 0.87 0.39 0.39 0.39 0.29
Noradrenaline (mcg/kg/min) 0.41 1.23 2.0 2.0 1.34
MBP - mean blood pressure; PAP - pulmonary arterial pressure; CVP - central venous pressure; PCP - pulmonary capillary pressure; SVR - systemic vascular
resistance; PVR - pulmonary vascular resistance.
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